Rueil Malmaison, France

Iuliana Botez

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Oncodesign Precision Medicine. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Iuliana Botez. Retrieved from https://idiyas.com/inventor/iuliana-botez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Iuliana Botez - Innovator in Precision Medicine

Introduction: Iuliana Botez is a talented inventor based in Rueil Malmaison, France. She is currently associated with Oncodesign Precision Medicine, where she contributes to advancements in the field of medical research. Although she does not hold any granted patents, her work is focused on developing innovative solutions for cognitive disorders.

Latest Patent Applications: Iuliana's latest patent applications include "NEW MACROCYCLIC LRRK2 KINASE INHIBITORS - Compounds of Formula (I): Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): wherein: Medicinal products containing the same which are useful in treating cognitive disorders associated with pathologies of the central nervous system." This application highlights her commitment to addressing significant health challenges.

Conclusion: Iuliana Botez is making strides in the field of precision medicine, and her ongoing research has the potential to impact the treatment of cognitive disorders significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…